TW587936B - Pharmaceutical composition containing proton pump inhibitors - Google Patents

Pharmaceutical composition containing proton pump inhibitors Download PDF

Info

Publication number
TW587936B
TW587936B TW089103033A TW89103033A TW587936B TW 587936 B TW587936 B TW 587936B TW 089103033 A TW089103033 A TW 089103033A TW 89103033 A TW89103033 A TW 89103033A TW 587936 B TW587936 B TW 587936B
Authority
TW
Taiwan
Prior art keywords
scope
patent application
item
composition according
propylene glycol
Prior art date
Application number
TW089103033A
Other languages
English (en)
Inventor
Keith Freehauf
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of TW587936B publication Critical patent/TW587936B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

A7 —----- -B7_________ 五、發明說明(1 ) 發明概要 本發明係有關一種經改良的口服奥米咪唑糊劑調配物。 發明背景 奥米咪唑係一種有抑制H+K七ATp酶作用之胃酸分泌強效 抑制劑,該酶涉及側膜細胞產生氫離子的最終步驟,且奥 米咪唑已用於治療與胃酸有關的疾病,如人類的胃及十二 ^腸/貝瘍。消化道潰瘍在某些動物亦常見,特別是馬匹。 雖然馬匹胃-十二腸潰瘍的病因學尚未確立,但似乎在某 些狀況下壓力扮演重要角色。 奥米咪唑對酸極不安定且因而其口服調配物有腸溶衣。 有腸/合衣的凋配物造價筇貴且費時,並需要精細的技術及 $又備。有腸溶衣的調配物的另一個缺點是易受潮。 W0 94/25070揭示含有質子幫浦抑制劑且有腸溶衣的乾 燥顆粒形式口服組合物經與膠化劑混合,然後該混合物可 在扠藥㈤製成似糊劑之凝膠。因此該組合物需要塗覆腸溶 衣,而伴布上述與此碉配物有關的缺點。此外,因爲這類 /然凝膠在室溫下長期儲存期間不安定,故其不能以現成調 配物裳迻及販售,而是必須在投藥時臨時製備,使其不便 於利用。 u S專利5,708,017説明了質子.幫浦抑制劑之糊劑調配 物,其包括質子·幫浦抑制劑、增稠劑、鹼化劑及疏水的 油性液態載體。 發明之詳細説明 本發明k供一種經改良的奥米咪唑糊劑調配物,其包括· -4 - 本纸張尺度適用中國國家標準(CNS)A4 --- (請先閱讀背面之注意事項再填寫本頁) ---- 訂--- 經濟部智慧財產局員工消費合作社印制π 587936 A7 137 五、發明說明(2 (a)約1%至60% w/w之奥米味哇, (b )約0.1 %至2% w/w之二至四種驗化劑, (c )約1 %至3 % w/w之增稠劑,及 (d)約30%至95% w/w之疏水的油性液態載體,包括 (i) 植物油及 (i i )中鏈脂肪酸之三酸甘油酯或中鏈脂肪酸之丙 二醇二酯。 奥米咪唑係經揭示於US專利4,255,432。奥米咪唑在本 發明中之含量並非特別關鍵性,只要該藥產品保持爲半固 態製劑;一般可耐受高達約6〇% w/w之奧米咪唑。奧米咪 唑的含量較宜約爲或低於50% w/w,且更宜約自3 〇至4〇% w/w ° 合適的鹼化劑是如醫藥上可接受的胺鹼,如單乙醇胺、 二乙醇胺、三乙醇胺或羧酸之鹽類如乙酸鈉、檸檬酸鈉、 花楸酸鉀、硬脂酸鈉等等。最好鹼化劑之一是花楸酸鉀, 且一或兩種鹼化劑可選自胺鹼如單乙醇胺及一個羧酸鹽如 硬脂酸鈉。該驗化劑之含量係足以提供非酸性的環境給對 酸不安定的奥米咪唑;典型地,該鹼化劑之總含量爲自 0 . 1至2% w/w且最好約自!至! 5% w/w。 該增稍劑可爲任何μ上可接受的非水溶性或部分非水 溶性増稠劑;實例包括二氧切、臘如海賴或經氯化的 海捏油、石壞、絲硬脂醇等等。較宜的疏水性増稠劑係經 氫化的海狸油。增稠劑的含量係約最終組合物之〇 5❶〆〇至 1 0% w/w ;最好,其約1至2% w/w。 (請先閱讀背面之注意事項再填寫本頁) ---- — l· — — 訂- 經濟部智慧財產局員工消費合作社印則衣 5- 587936 A7 B7 五、發明說明( 3 經濟部智慧財產局員工消費合作社印製 該疏水的油性液態載體包含(i )植物油及(i i )中鏈脂肪 酸之三酸甘油酯或中鏈脂肪酸之丙二醇二酯。植物油的實 例包括杏仁油、棉籽油、橄欖油、花生油、葵花油、芝麻 油及大豆油。較宜的植物油係芝麻油。中鏈脂肪酸係凡碳 鏈長自八至十二之脂肪酸;最好該脂肪酸爲飽和脂肪酸。 較宜的三酸甘油酯及丙二醇二酯係癸酸/辛酸三酸甘油酯 及丙二醇癸酸酯/辛酸酯(亦稱爲丙二醇辛酸酯癸酸酯)。 癸酸/辛酸三酸甘油酯及丙二醇癸酸酯/辛酸酯係可商購之 產品如凡以麥格利奥(Miglyol)®商品名(休斯亞美利加股份 有限公司,紐澤西)銷售者。更宜的疏水油性液態載體包 含芝麻油及丙二醇癸酸鹽/辛酸酯(如麥格利奥⑧84〇)。該 疏水性的載體含量係約3 0 %至95% w/w,取決於糊劑中其 他賦形劑的含量。最好該疏水性的載體含量約5 〇至8〇% w/w。在該疏水性的載體中植物油對三酸甘油酯之比例範 圍約自1 : 3至5 : 1 ;最好約自1 ·;[至2 : 1。 本發明之組合物可包括其他常用於人類及家畜藥物之調 配物的成分。可加入例如,香料如焦糖、胡蘿笥、蘋果、 肉桂及臘腸香料;呈色劑如氧化鐵、二氧化鈦、鋁沉澱色 料:甜味劑如糖、糖精鈉;防腐劑如對氧苯甲酸;抗氧化 劑如BHT、BHA ;分散劑如硬脂酸鈣;及黏度調整劑如白 臘或合成臘如甘油基參二十二碳酸鹽(tribehenate )、甘油 基三肉且寇酸酯、經氫化的可可甘油酯。 本發明組合物之製備可分散粉末形式之奧米咪唑於含除 增稠劑以外的任何其他賦形劑之疏水液態載體中。然後加 -6- 表纸狀度適用帽國家標^公楚) (請先閱讀背面之注意事項再填寫本頁) ---- ϋ l· 1 n · =口 經濟部智慧財產局員工消費合作社印制代 587936 A7 _____ B7 五、發明說明(4 ) 增稠劑至該混合物中並攪拌以達需要之黏稠度。本發明組 合物之製備亦可分散賦形劑於疏水的油性液態載體中,接 著添加增稠劑’且若有需要可額外加入植物油以達需要之 黏稠度;於產生之混合物中加入粉末形式的奥米咪唑且充 分混合整個混合物以分散奥米咪唑。因此取得之糊劑調配 物可用以填充配藥注射筒,其可直接用以投與有效藥給需 要治療之動物。 本發明之奥米咪唑糊劑調配物具有超越以往奥米咪唑糊 劑調配物之經改良特性。本發明之調配物具有較好的物理 及化學安定性表現形式,且提供較高的藥物生物效性。 本發明之組合物係對治療人類及動物消化道潰瘍疾病有 用。在動物其可用於經口遞送奥米咪唑於系統性效果。該 組合物也可用以遞送奥米咪唑給吞嚥固態劑型如有腸溶衣 的錠劑及膠囊有困難的人。該組合物可直接投至需要抗潰 瘍療法的動物口中,如馬匹;最好利用糊劑配藥注射筒幫 助投藥。此糊劑之黏調度需足使其一旦經置於動物舌背上 就不易滴出或被排出。該糊劑特別不含氣泡以增進下藥之 正確性。此調配物之另一優點是可投予個別之劑量。 該組合物的投藥量可根據所治療之特姝動物種類、該疾 病的嚴重性、該生病動物之生理狀況及其他因素變化。凡 熟稔治療潰瘍之技藝的醫師或售醫可輕易決定對於接受治 療之特定宿主適當之劑量。通常,可用之劑量範園係約自 0.2 mg/kg 至 20 mg/kg。 以下實例係提供更完整的闡明本發明,且不應被以任何 本纸張&度適用中國國家標準(CNS)A4規格(21〇 χ 297"^·^—~----------- (請先閱讀背面之注意事項再填寫本頁) ---- 587936 A7 B7 五、發明說明(5) 方式解釋爲本發明範圍之限制。 實例成分 奥米咪唑鹼 花楸酸神 硬脂酸鈉 硬脂酸飼 單乙醇胺 黃氧化鐵 肉桂油 經氫化的海狸油 丙二醇辛酸酯癸酸酯 芝麻油 互全率w/w 37.0 0.20 0.10 1.0 0.10 0.20 0.30 1.25 25.0qs (請先閱讀背面之注意事項再填寫本頁) ---- 經濟部智慧財產局員工消費合作社印制π 加花楸酸鉀(0.50 kg)、硬脂酸鈣(2·50 kg)、硬脂酸納 (0·25 kg)及黃氧化鐵(〇.50 kg)至二重錐形混合機並混合成 分散粉末。使產生之粉末通過6 0篩孔之篩網並以高速研 磨。收集該經研磨之粉末預拌物於聚乙烯袋中以用於糊劑 之製造。 在一合適大小之垂直螺旋半固態糊劑攪拌器中加入丙二 醇辛酸S旨癸酸醋(62.5 kg)及芝麻油(37.5 kg)。若有需要, 調整該液態混合物之溫度至約低於25°C,並打開攪掉螺 旋。打開糰塊破碎機同時加該經研磨之粉末預拌物、單乙 醇胺(0.25 kg)、及肉桂油(0.75 kg)至該攪拌器。然後,力口 經氫化的海狸油(3 · 13 kg )至該攪拌器,並攪拌至該產品溫 -8- 本纸張尺度遠用中國國家標準(CNS)A4規格(210 X 297公釐) -----訂 ---- 587936 A7 B7 五、發明說明(6 ) 度達50 ±5°C。停止該攪拌螺旋及該糰塊破碎機並靜置該 批容器中的内容物30土5分鐘以確保完成凝膠過程。^ μ 打開冷卻水同時加剩餘之芝麻油(49 6 kg)至攪拌器。打 開攪拌螺旋及糰塊破碎機約二分鐘以分散原料炊後停止。 將奥米咪❹末(92.5kg)分爲8_10份加至攪拌器;在每加 二 =打開該攪拌器一段足以濕潤大部分之粉末的時間 ==力:入下—份。在加入所有的奥米備,再繼 碎乂完全分散奥米咪峻;然後打開該糰塊破 檀掉1〇分鐘以確保完全之均質性。將產生 <糊劑包裝於針筒中。 (請先閱讀背面之注意事項再填寫本頁) ----- i^i ϋ J ,• — ΜΜ βΙΗΜ ΜΒΜ MM I I · ♦ 經濟部智慧財產局員工消費合作社印製

Claims (1)

  1. 587936 第089103033號專利申請案 中文申請專利範圍替換本(92年4月) A8 B8 C8 D8 六、申請專利範圍 I# i φ. ν .: ^ I 衣年月曰 補充 1· 一種口服醫藥組合物,其包括: (a) 約1 %至60% w/w之奥米咪唑’ (b )約〇 · 1 %至2 % w / w之二至四種鹼化劑’ (c )約1 %至3 % w / w之增桐劑’及 (d )疏水性的油性液態媒劑包括 (i) 植物油及 (Π)中鏈脂肪酸之三酸甘油酯或中鏈脂肪酸之丙 二醇二酯。 2·根據申請專利範圍第1項之組合物,其中該增稠劑係經 氮化的海捏油。 3·根據申請專利範圍第1項之組合物,其中該疏水性的液 態載體包含丙二醇癸酸鹽/辛酸酯及植物油。 4·根據申請專利範圍第丨項之組合物,其中該疏水性的液 態載體包含芝麻油及中鏈脂肪酸之三酸甘油酯或中鏈脂 肪酸之丙二醇二酯。 5.根據申請專利範圍第1項之組合物,其中該疏水性的液 態載體包含丙二醇癸酸鹽/辛酸酯及芝麻油。 6·根據申請專利範圍第1項之組合物,其中鹼化劑之一為 花楸酸4甲。 7_根據申請專利範圍第1項之組合物,其中該鹼化劑係花 楸酸鉀、硬脂酸鈉及單乙醇胺。 8·根據申請專利範圍第1項之組合物,其中奥米咪唑含量 約為3 0至40% w/w。 9·根據申請專利範圍第1項之組合物,其中該鹼化劑總含 本紙張尺度國家標準(0^八4規格(2ΐο χ 297公爱) 587936 8 8 8 8 A BCD 々、申請專利範圍 量係自約1至1.5% w/w。 10. 稂據申請專利範圍第1項之組合物,其中該疏水性的油 性液態媒劑含量約為30%至90% w/w。 11. 根據申請專利範圍第1項之組合物,其中該疏水性的油 性液態媒劑含量約為50%至80% w/w。 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
TW089103033A 1999-02-23 2000-02-22 Pharmaceutical composition containing proton pump inhibitors TW587936B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12125399P 1999-02-23 1999-02-23

Publications (1)

Publication Number Publication Date
TW587936B true TW587936B (en) 2004-05-21

Family

ID=22395498

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089103033A TW587936B (en) 1999-02-23 2000-02-22 Pharmaceutical composition containing proton pump inhibitors

Country Status (31)

Country Link
US (1) US6316481B1 (zh)
EP (1) EP1156806B1 (zh)
JP (1) JP2002537337A (zh)
KR (1) KR100701448B1 (zh)
CN (1) CN1227009C (zh)
AR (1) AR029615A1 (zh)
AT (1) ATE263562T1 (zh)
AU (1) AU771061B2 (zh)
BG (1) BG65291B1 (zh)
BR (1) BR0008403A (zh)
CA (1) CA2362932C (zh)
CO (1) CO5140102A1 (zh)
CZ (1) CZ301647B6 (zh)
DE (1) DE60009675T2 (zh)
DK (1) DK1156806T3 (zh)
EA (1) EA004683B1 (zh)
ES (1) ES2216870T3 (zh)
HK (1) HK1041650A1 (zh)
HR (1) HRP20010615B1 (zh)
HU (1) HU228181B1 (zh)
IL (1) IL144131A0 (zh)
ME (1) ME00864B (zh)
NO (1) NO328863B1 (zh)
NZ (1) NZ512771A (zh)
PL (1) PL195783B1 (zh)
PT (1) PT1156806E (zh)
RS (1) RS50023B (zh)
SK (1) SK286371B6 (zh)
TW (1) TW587936B (zh)
WO (1) WO2000050038A1 (zh)
ZA (1) ZA200106104B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
NZ522450A (en) 2000-05-30 2004-07-30 Merial Ltd Methods for prevention of ulcers
BR0115989A (pt) 2000-12-07 2004-01-13 Altana Pharma Ag Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
CA2430816C (en) 2000-12-07 2012-05-15 Altana Pharma Ag Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
JP4634144B2 (ja) 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
IN2012DN00359A (zh) 2009-07-20 2015-05-22 Vetegen Llc
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2013165468A1 (en) * 2012-05-02 2013-11-07 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
GB2524351B (en) * 2013-10-18 2016-12-14 Norbrook Lab Ltd Proton Pump Inhibitor Paste Compositions
EP3057571B1 (en) * 2013-10-18 2019-03-06 Norbrook Laboratories Limited Proton pump inhibitor paste compositions
FI3386507T3 (fi) 2015-12-08 2023-09-06 Luoda Pharma Ltd Menetelmiä ja koostumuksia mahahaavojen hoitoon
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
ES2723873B1 (es) * 2018-03-01 2020-05-13 Hernan Ma Carmen Batanero Medicamento combinado con omeprazol y vitamina B12
CN112972481A (zh) * 2021-03-18 2021-06-18 华农(肇庆)生物产业技术研究院有限公司 药物组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
DK130287D0 (da) 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors

Also Published As

Publication number Publication date
EP1156806B1 (en) 2004-04-07
EA004683B1 (ru) 2004-06-24
SK12062001A3 (sk) 2001-12-03
DE60009675T2 (de) 2005-03-24
DK1156806T3 (da) 2004-08-02
BR0008403A (pt) 2002-01-29
CN1341022A (zh) 2002-03-20
CN1227009C (zh) 2005-11-16
KR20010102297A (ko) 2001-11-15
NZ512771A (en) 2003-02-28
AU771061B2 (en) 2004-03-11
KR100701448B1 (ko) 2007-03-30
PL195783B1 (pl) 2007-10-31
ES2216870T3 (es) 2004-11-01
NO20014074L (no) 2001-08-22
EA200100905A1 (ru) 2002-02-28
CO5140102A1 (es) 2002-03-22
HK1041650A1 (en) 2002-07-19
IL144131A0 (en) 2002-05-23
HUP0200325A3 (en) 2003-05-28
ATE263562T1 (de) 2004-04-15
PT1156806E (pt) 2004-07-30
ME00864B (me) 2008-09-29
RS50023B (sr) 2008-09-29
CZ301647B6 (cs) 2010-05-12
EP1156806A1 (en) 2001-11-28
JP2002537337A (ja) 2002-11-05
HRP20010615A2 (en) 2002-12-31
NO328863B1 (no) 2010-05-31
BG105754A (en) 2002-03-29
DE60009675D1 (de) 2004-05-13
NO20014074D0 (no) 2001-08-22
AU3368700A (en) 2000-09-14
HRP20010615B1 (en) 2011-03-31
CA2362932A1 (en) 2000-08-31
HU228181B1 (en) 2013-01-28
ZA200106104B (en) 2002-12-24
CA2362932C (en) 2010-11-30
CZ20013058A3 (cs) 2001-11-14
SK286371B6 (sk) 2008-08-05
HUP0200325A2 (en) 2002-06-29
WO2000050038A1 (en) 2000-08-31
US6316481B1 (en) 2001-11-13
AR029615A1 (es) 2003-07-10
YU50401A (sh) 2004-05-12
BG65291B1 (bg) 2007-12-28
PL350729A1 (en) 2003-01-27

Similar Documents

Publication Publication Date Title
TW587936B (en) Pharmaceutical composition containing proton pump inhibitors
JP4603631B2 (ja) プロトンポンプ阻害剤を含有する医薬組成物
TW492876B (en) New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture
NZ205894A (en) Pharmaceutical compositions containing mopidamol(2,6-bis(diethanolamino)-4-piperidino-pyrimido(5,4-d)pyrimidine)
JP2000514406A (ja) アルギン酸から成る経口投与製剤用腸溶性被膜
US9040091B2 (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
JP3224379B1 (ja) 8−クロロ−6,11−ジヒドロ−11−(4−ピペリジリデン)−5H−ベンゾ[5,6]シクロヘプタ[1,2−b]ピリジンの経口用組成物
WO2006026829A1 (en) Stable paste composition of enteric coated acid labile active agent and use thereof
EP0263493A2 (de) Pharmazeutische Präparate zur verbesserten gastrointestinalen Resorption
CN102579403B (zh) 盐酸度洛西汀药物组合物
WO2018222164A9 (en) USE OF HERB-BASED PREPARATION CONTAINING POUPINE OIL CONTAINING POULTRY OIL IN THE TREATMENT OF BPH
GB2394895A (en) Proton pump inhibitor composition in paste form
US20050175686A1 (en) Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
MXPA01008525A (en) Pharmaceutical composition containing proton pump inhibitors
GB2614129A (en) Chewable semi-solid milk-based drug delivery platform and method for the preparation of milk-based drug compositions and its use
CN1138826A (zh) 5-硝基咪唑衍生物微粒
WO2018222163A2 (en) Use of an herbal formula containing pumpkin seed oil in the treatment of overactive bladder and urinary incontinence of the lower urinary system symptoms

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent